Mithra Releases Invitation to its General Ordinary and Extraordinary Securities holders' Meeting

Liege, Belgium - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health announces the invitation to its ordinary and extraordinary securities holders' meeting that will be held on Thursday May 19 2022 at 2:00 PM (CEST).

The notice for the General Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19

Considering the COVID-19 pandemic, it is possible that our governments and public authorities may adapt the conditions and modalities for physical participation in the General Meeting. We reserve our rights to issue additional instructions in this regard. These measures are in the interest of the health of the individual security holders, as well as of the Company's employees and other persons responsible for organizing the General Meeting. Therefore, the Company recommends that shareholders of the Company who wish to participate in the General Meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision granted to Fanny Rozenberg, Secretary of the Board of Directors of the Company, and not to attend the General Meeting personally. The Company will grant access to the General Meeting to security holders, proxy holders and any other persons only to the extent permitted by the measures taken or to be taken by the authorities, as applicable at the time of the General Meeting, and always taking into account the recommendations of the authorities, as well as safety and health considerations. In addition, holders of the Company's securities are encouraged to exercise their right to ask questions in writing concerning the items on the agenda of the General Meeting. Details of how to participate in the Ordinary Shareholders' Meeting are set out in this notice of meeting. The Company will also set up a videoconference to enable holders of the Company's securities who have duly registered for the General Meeting and who have duly completed and returned the notice of participation to the Company to follow the General Meeting remotely.

Videoconferencing will not be considered as an electronic means of communication to attend and vote at the General Meeting, as referred to in Article 7:137 of the Companies and Associations Code but will be an additional means for the security holders to follow the General Meeting. The Company will closely monitor the situation and applicable actions and may provide further updates relevant or impacting the Ordinary General Meeting on the Company's website: investors.mithra.com. All procedures for attending the ordinary and extraordinary shareholders' meetings are indicated in the present meeting's invitation.

Contact:

Maud Vanderthommen

Press

T: [phone]

E: [e-mail]

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle , Mithra is now focusing on its second product Donesta , the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements'. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believes', 'estimates,' 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'continue', 'ongoing', 'potential', 'predict', 'project', 'target', 'seek' or 'should', and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(C) 2022 Electronic News Publishing, source ENP Newswire